Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs IQVIA Holdings Inc. Common Stock (IQV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs IQVIA Holdings Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.34 (market cap $12.58B), while IQVIA Holdings Inc. Common Stock trades at $260.31 (market cap $42.61B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 3.4× Halozyme Therapeutics Inc. Common Stock's market cap, and IQVIA Holdings Inc. Common Stock is more actively traded (988,398 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and IQVIA Holdings Inc. Common Stock for 1 Days on average.
| HALO | IQV | |
|---|---|---|
Market Cap | $12.58B | $42.61B |
Volume | 2,179,278 | 988,398 |
Sector | Health | Health |
52-Week High | $115.22 | $275.02 |
52-Week Low | $61.63 | $156.66 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $56.77B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →
